Valuation
Is the price right?3/3 inputs reported · High confidence
Weaker than most peers on:
- ▼ Earnings yield
- ▼ EBITDA yield
Behind the score
Sector-normalized EBITDA, earnings, and free cash flow yields.
Bringing the fundamentals into focus…
Price as of close on Nov 3, 2026 · Financials updated Oct 8, 2026
3/3 inputs reported · High confidence
Weaker than most peers on:
Sector-normalized EBITDA, earnings, and free cash flow yields.
3/3 inputs reported · High confidence
Stronger than most peers on:
Revenue and earnings-per-share growth over one year, and revenue growth over three years.
3/3 inputs reported · High confidence
Weaker than most peers on:
Return on invested capital, operating margin, and return on assets.
3/3 inputs reported · High confidence
Weaker than most peers on:
Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
No major changes
Worth watching: Guardant Health is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.
| Previous quarter | Latest quarter | Change | |
|---|---|---|---|
| Revenue (12 months) | 1.1B USD | 1.2B USD | +9.5% |
| Net income (12 months) | −433.2M USD | −453.5M USD | +4.7% |
| Operating margin | -41.4% | -39.7% | +1.7 pts |
| Free cash flow (12 months) | −237.1M USD | −240.7M USD | +1.5% |
| Debt | 1.5B USD | 1.5B USD | −0.0% |
| Cash | 989.3M USD | 1.1B USD | +6.5% |
| Shares outstanding | 132.6M | 134.2M | +1.2% |
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Valuations in Diagnostics & Research are within their usual range since Nov 2018.
| Key ratios | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | Change |
|---|---|---|---|---|---|---|
| Gross margin | — | — | 59.7% | 60.8% | 64.5% | ▲ 3.7 pts |
| Operating margin | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% | ▲ 15 pts |
| Net margin | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% | ▲ 17 pts |
| Return on assets (ROA) | -17.5% | -40.7% | -26.8% | -29.4% | -20.7% | ▲ 8.7 pts |
| Return on equity (ROE) | -59.7% | -1087.7% | -302.1% | — | — | — |
| Free cash flow margin | -76.0% | -86.1% | -61.3% | -37.2% | -23.7% | ▲ 13 pts |
| Current ratio | 5.72× | 6.17× | 6.54× | 4.68× | 4.84× | ▲ 3.5% |
| Quick ratio | 5.57× | 5.90× | 6.24× | 4.36× | 4.56× | ▲ 4.5% |
| Interest coverage | -159.49× | -211.24× | -219.06× | -171.87× | -112.20× | ▲ 35% |
Price history is added with the daily price update and will appear after the next one.